Lori Ricklefs, DO
Family Medicine · Rocky Mount, NCNPI 1376864199
Payments from drug & device makers
Across 311 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$848
- AstraZeneca$683
- Amgen$474
- AbbVie$439
- Lilly USA, LLC$422
- Pfizer$250
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,02199%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $848 |
| AstraZeneca(2 entities) | 37 | $683 |
| Amgen | 33 | $474 |
| AbbVie(2 entities) | 25 | $439 |
| Lilly USA, LLC | 26 | $422 |
| Pfizer | 16 | $250 |
| GSK | 14 | $216 |
| Merck | 14 | $207 |
| Boehringer Ingelheim | 10 | $181 |
| Bayer | 11 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $154 |
| Hikma Pharmaceuticals USA | 5 | $95 |
| Idorsia Pharmaceuticals US Inc | 5 | $87 |
| Astellas Pharma US Inc | 4 | $76 |
| Abbott | 4 | $74 |
| Amarin Pharma, Inc. | 4 | $68 |
| Eisai Inc. | 4 | $68 |
| Exact Sciences | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 4 | $53 |
| Amneal Pharmaceuticals LLC | 2 | $49 |
| Grifols USA, LLC | 2 | $49 |
| Sanofi Pasteur Inc. | 2 | $49 |
| Esperion Therapeutics, Inc. | 2 | $43 |
| Corium, LLC | 2 | $37 |
| C2n Diagnostics, LLC | 1 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Shield Therapeutics Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Sonex Health, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $13 |
How this compares
$5,080 in reported general payments places this provider in the 85th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $229,414 |
| EliquisApixaban | 144 | $134,214 |
| RybelsusSemaglutide | 57 | $96,598 |
| FarxigaDapagliflozin Propanediol | 90 | $81,026 |
| JardianceEmpagliflozin | 66 | $75,323 |
| TrulicityDulaglutide | 47 | $70,742 |
| MounjaroTirzepatide | 25 | $45,685 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $44,674 |
| JanuviaSitagliptin Phosphate | 44 | $36,334 |
| MyrbetriqMirabegron | 52 | $31,735 |
| LinzessLinaclotide | 38 | $30,331 |
| EntrestoSacubitril/Valsartan | 29 | $26,857 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $19,600 |
| Repatha SureclickEvolocumab | 18 | $16,332 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $14,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $848 | $326,011210 claims |
| PfizerEliquis | $250 | $134,214144 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $422 | $116,42772 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $683 | $108,741144 claims |
| Boehringer IngelheimJardiance, Tradjenta | $181 | $84,21683 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $216 | $59,19776 claims |
| MerckJanuvia | $207 | $36,33444 claims |
| AbbVieLinzess, Synthroid | $439 | $33,06871 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $31,73552 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $11,46718 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $49 | $2,406303 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Rocky Mount
- Richard MichalRocky Mount$97K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.